Primary Outcome Measures ORR Inclusion Criteria Subjects must provide informed consent prior to initiating any study-specific procedures. Male or female subjects aged ≥18 and ≤75 years. Histologically/cytologically confirmed malignant mesothelioma (MM), including malignant pleural mesothelioma (PM) and malignant peritoneal mesothelioma (PeM). Subjects with MM unsuitable for radical resection and/or radiotherapy[…]
Pleural Mesothelioma
Empyema Challenges After Pleural Mesothelioma Surgery
Pleural mesothelioma, a cancer linked to asbestos exposure, is very tough to treat. Surgery is one part of multimodal therapy that aims to remove as much cancer as possible. Surgery is a very useful tool in the treatment of mesothelioma, but after surgery, complications can occur. One complication can be[…]
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study (NECIM)
Primary Outcome Measures To assess the percentage of successful completion of a neoadjuvant double chemotherapy / double immunotherapy regimen followed by surgery in a selected group of T2-T3 (according to TNM 9) patients with pleural mesothelioma. Secondary Outcome Measures Toxicity of the neoadjuvant double chemotherapy / double immunotherapy regimen and[…]
New Clinical Trial is Testing CAR-T Cell Therapy for Mesothelioma and Other Hard to Treat Tumors
A new clinical trial that launched this month is testing a new immunotherapy regimen that could offer hope to people with mesothelioma and other hard to treat cancers. It will be examining an experimental treatment that utilizes CAR-T cells, an immune cell engineered to find and attack cancer cells. The[…]
An International Study on Pediatric Patients With Rare Tumors. (PARTNER)
Primary Outcome Measures Epidemiology Use of International Recommendations Survival of children and adolescents (0-18 years) affected by Very Rare Tumors Inclusion Criteria Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. Written informed consent from the patient and/or[…]
Immunotherapy Benefits and Drawbacks for Treating Mesothelioma
Mesothelioma is a rare and aggressive cancer that creates multiple challenges for patients and caregivers. Immune checkpoint inhibitors have recently shown promise to bring hope to people suffering from this devastating cancer. New data from Australia, however, is questioning their effectiveness and safety. Patients and caregivers must understand immunotherapy and[…]
MARS 2 Trial for Mesothelioma
Pleural mesothelioma is a rare and aggressive cancer that is linked to asbestos exposure. It affects the lining of the lungs. Every year, there are over 2,500 people in the United Kingdom that are diagnosed with the cancer. A study known as MARS 2 investigated if adding surgery to chemotherapy[…]
Multimodal Therapy to Treat Pleural Mesothelioma
Malignant pleural mesothelioma is a deadly cancer that is mainly caused by asbestos exposure. It affects the lungs’ lining. It is a very hard to treat cancer because it is very aggressive and is often diagnosed at a late stage. New surgical and therapeutic methods are offering hope though. A[…]
Prospective Data Collection Initiative on Thoracic Malignancies (DuTOC)
Primary Outcome Measures Progression free survival Secondary outcome Measures Disease free survival Overall survival Health related quality of life Inclusion Criteria Age ≥ 18 years; Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board); Informed consent for longitudinal observational data collection; Exclusion Criteria Mentally[…]
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)
Primary Outcome Measures Overall Survival Secondary Outcome Measures Progression Free Survival Best Response: Objective Response Rate (ORR) Best Response: Disease Control Rate (DCR) Best Response: Clinical Benefit Rate (CBR) Other Outcome Measures Survival Rate at 12 Months Survival Rate at 18 Months Survival Rate at 24 Months Survival Rate at[…]
Skip to content